This trial is active, not recruiting.

Conditions infant mortality, morbidity
Treatment vitamin a
Phase phase 4
Sponsor Bandim Health Project
Collaborator March of Dimes
Start date November 2004
Trial size 7600 participants
Trial identifier NCT00168610, 6-FY04-51, 6-FY04-51-VITA2


In the present study the investigators wish to address the effects of different doses of vitamin A supplementation in low and normal birth weight infants.


- Vitamin A supplementation administered at birth together with BCG vaccination is associated with a 30% reduction in infant mortality and morbidity during the first year of life in both normal and low birth weight infants.

- A lower dose of vitamin A may be even more beneficial than a high dose.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Intervention model parallel assignment
Masking double-blind
Primary purpose prevention

Primary Outcomes

time frame:
time frame:

Secondary Outcomes

Adverse effects
time frame:
Tuberculin reaction
time frame:
BCG scarring
time frame:
time frame:
Vitamin A status
time frame:
Cytokine responses
time frame:
time frame:
time frame:
time frame:
Respiratory syncytial virus (RSV) infection
time frame:
All primary and secondary outcomes will be analysed for interactions between vitamin A and sex and last vaccine received.
time frame:

Eligibility Criteria

Male or female participants up to 5 months old.

Inclusion Criteria: - Normal birth weight: belonging to the study area - Low birth weight: being born at the national hospital Exclusion Criteria: - Overt illness - Signs of vitamin A deficiency - Previous BCG vaccination

Additional Information

Official title Should Infants Receive High-dose Vitamin A Supplementation With BCG Vaccine at Birth in Developing Countries? Randomized Prospective Studies in Guinea-Bissau
Principal investigator Peter Aaby
Description Vitamin A deficiency is common in low-income countries. Vitamin A supplementation to children above 6 months of age reduces all-cause mortality by 23% to 30%. Studies on vitamin A supplementation in infants younger than 6 months of age have reported inconsistent effects on mortality. Studies providing supplementation between 1 and 5 months of age have found no effect or even a negative effect. However, the only two studies of supplementation at birth, both conducted in Asia, showed substantial significant reductions in infant all-cause mortality. The beneficial effect of neonatal vitamin A supplementation may be a result of correcting the congenital vitamin A deficiency resulting from maternal vitamin A deficiency. On the other hand, it has been speculated that the beneficial effect of vitamin A supplementation given at birth may in part be explained by a synergistic effect of vitamin A supplementation and BCG vaccination given at the time of birth. The protective effect on mortality of vitamin A supplementation given at birth needs to be confirmed in an African population. Furthermore, none of the two previous studies have reported data on the vaccination status of the included infants. In the proposed studies, the effect on mortality and morbidity of giving vitamin A supplementation simultaneously with BCG vaccination at birth to both normal and low birth weight infants will be investigated in an African population. Furthermore, the effects of vitamin A supplementation will be evaluated with respect to effect on growth, the response to BCG vaccination, infant vitamin A status and infant cytokine profile, malaria, measles, rotavirus infection and RSV infection. The mechanisms behind the effects of vitamin A will be evaluated. The potential interactions between vitamin A, sex and vaccines will be taken into account in all analyses. This will be done in two studies of newborn children. Study A includes 6,000 normal birth weight infants (> 2500 g) randomized to 50,000 or 25,000 IU vitamin A or placebo given simultaneously with BCG vaccine. Study B includes 1,600 low birth weight infants (< 2500 g) randomized to vitamin A or placebo and early BCG or late BCG in a two-by-two factorial design. The studies take place in Guinea-Bissau, West Africa. The study area consists of five districts in the capital of Guinea-Bissau. The Bandim Health Project has been working in the study area for almost 25 years, and a demographic surveillance system has been established and has functioned for many years.
Trial information was received from ClinicalTrials.gov and was last updated in November 2013.
Information provided to ClinicalTrials.gov by Bandim Health Project.